Warning letter summary

Genzyme Ireland Limited - CGMP/Deviations/Biologics License Application (BLA)

Source-linked warning-letter readout for QA, RA, supplier-quality, and response-support triage. Use it to see the control signal before you open the full FDA letter.

2026-06-30Pharma / drug qualityPublic FDA source
Ask about response supportOpen FDA source

What FDA posted

Posted 06/30/2026. Issued 06/22/2026. Center for Biologics Evaluation and Research (CBER). CGMP/Deviations/Biologics License Application (BLA).

Open FDA source

Signal read

  • FDA tied the letter to licensed biologics manufacturing and CBER oversight.
  • The cited pattern centers on quality-unit oversight, data integrity, laboratory records, deviation handling, and product-impact assessment.
  • The practical reader is a sterile, biologics, QA, RA, supplier-quality, or remediation team watching where FDA expects stronger evidence.

How to use this page

Turn a source link into a review question.

For internal teams

Use the signal notes to decide whether QA, RA, supplier quality, laboratory operations, or site leadership should review the letter.

For advisors and consultants

Use the source link and signal notes as a fast screen for whether the matter fits your response, remediation, data-integrity, or inspection-readiness work.

Response support

Need help reading or responding to a warning letter?

FDA Warning Monitor can route qualified public-source inquiries to response specialists. Do not send confidential documents through this form.

Response-help intake

Use this if you received a letter, advise a company that did, or need a specialist read on a public warning-letter pattern.

Do not send confidential documents, trade secrets, protected health information, account credentials, or non-public FDA correspondence through this form.

Boundary

Use FDA as the authority.

Use the FDA source as the authoritative record. FDA Warning Monitor summarizes public source material for monitoring and referral triage only. It does not evaluate legal risk, recommend a corrective action plan, or represent FDA.